Background
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer.• Tumor Endothelial Marker 1 (TEM1/Endosialin/CD248) Enhances Wound Healing by Interacting with Platelet-Derived Growth Factor Receptors., PMID:30986375• TEM1/endosialin/CD248 promotes pathologic scarring and TGF-β activity through its receptor stability in dermal fibroblasts., PMID:38254097• Regulation of matrix reloading by tumor endothelial marker 1 protects against abdominal aortic aneurysm., PMID:39113704• Role of tumor endothelial marker 1 (Endosialin/CD248) lectin-like domain in lipopolysaccharide-induced macrophage activation and sepsis in mice., PMID:33737161• Tumor endothelial marker 1 is upregulated in heart after cardiac injury and participates in cardiac remodeling., PMID:35732643• Preclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1)., PMID:31993928• Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature., PMID:24642465• Endosialin: molecular and functional links to tumor angiogenesis., PMID:26774137• Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells., PMID:18187565• Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma., PMID:29304474